The present invention provides compositions and methods for the treatment of skin lesions. In particular, embodiments of the invention provide topical compositions useful in the treatment and alleviation of cutaneous symptoms associated with psoriasis, dermatitis and other dermatological conditions including ulcers or lesions, wherein the compositions contain CBD oil.

The present invention provides compositions and methods for the treatment of skin lesions. In particular, embodiments of the invention provide topical compositions useful in the treatment and alleviation of cutaneous symptoms associated with psoriasis, dermatitis and other dermatological conditions including ulcers or lesions, wherein the compositions contain CBD oil.

The present invention provides compositions and methods for the treatment of skin lesions. In particular, embodiments of the invention provide topical compositions useful in the treatment and alleviation of cutaneous symptoms associated with psoriasis, dermatitis and other dermatological conditions including ulcers or lesions, wherein the compositions contain CBD oil.

Composition for treatment and management of addiction and method of preparation thereof are disclosed herein. The disclosed herbal composition includes herb and mineral which facilitate in treating addiction. It may be used to treat addiction such as alcohol addiction, tobacco addiction, excessive smoking, drugs abuse etc. Further, the disclosed composition may also be instrumental in treating complications associated with addiction and withdrawal symptoms.

Composition for treatment and management of addiction and method of preparation thereof are disclosed herein. The disclosed herbal composition includes herb and mineral which facilitate in treating addiction. It may be used to treat addiction such as alcohol addiction, tobacco addiction, excessive smoking, drugs abuse etc. Further, the disclosed composition may also be instrumental in treating complications associated with addiction and withdrawal symptoms.

Composition for treatment and management of addiction and method of preparation thereof are disclosed herein. The disclosed herbal composition includes herb and mineral which facilitate in treating addiction. It may be used to treat addiction such as alcohol addiction, tobacco addiction, excessive smoking, drugs abuse etc. Further, the disclosed composition may also be instrumental in treating complications associated with addiction and withdrawal symptoms.

The invention discloses synergistic compositions comprising at least one component selected from extract(s) and fraction(s) or mixtures thereof derived from Sphaeranthus indicus in combination with at least one component selected from extract(s), fraction(s), active compound(s) or mixtures thereof derived from Terminalia chebula for improving the liver health. The invention further discloses method of improving the liver health in humans and animals by administering the compositions comprising at least one component selected from extract(s) and fraction(s) or mixtures thereof derived from Sphaeranthus indicus in combination with at least one component selected from extract(s), fraction(s), active compound(s) or mixtures thereof derived from Terminalia chebula.

The invention discloses synergistic compositions comprising at least one component selected from extract(s) and fraction(s) or mixtures thereof derived from Sphaeranthus indicus in combination with at least one component selected from extract(s), fraction(s), active compound(s) or mixtures thereof derived from Terminalia chebula for improving the liver health. The invention further discloses method of improving the liver health in humans and animals by administering the compositions comprising at least one component selected from extract(s) and fraction(s) or mixtures thereof derived from Sphaeranthus indicus in combination with at least one component selected from extract(s), fraction(s), active compound(s) or mixtures thereof derived from Terminalia chebula.

Disclosed herein are novel thrombolytic formula for safe and effective treatment of blood clots. In clinical trials, cats of various breeds and ages presented partial or full paralysis of one or more limbs, due to arterial thromboembolism (ATE). Average treatment ranged from 3 days to 2 weeks, depending on the clot size and time elapsed since clot was dislodged from the subject's heart. These are significant findings considering the lack of treatment options available in veterinary medicine for cats with HCM and ATE. Veterinarians often euthanize cats presenting ATE, as no safe and effective thrombolytic agent is currently available for veterinary use. Previous thrombolytics were shown to have an average mortality rate of 60% due to reperfusion injury and hemorrhaging. The disclosed formula, on the other hand, overcomes these shortcomings.

Disclosed herein are novel thrombolytic formula for safe and effective treatment of blood clots. In clinical trials, cats of various breeds and ages presented partial or full paralysis of one or more limbs, due to arterial thromboembolism (ATE). Average treatment ranged from 3 days to 2 weeks, depending on the clot size and time elapsed since clot was dislodged from the subject's heart. These are significant findings considering the lack of treatment options available in veterinary medicine for cats with HCM and ATE. Veterinarians often euthanize cats presenting ATE, as no safe and effective thrombolytic agent is currently available for veterinary use. Previous thrombolytics were shown to have an average mortality rate of 60% due to reperfusion injury and hemorrhaging. The disclosed formula, on the other hand, overcomes these shortcomings.